IRMD Company Profile and Key Details

IRMD has shown sold momentum, gaining 5.19% over the past week and 40.97% over the past quarter, though year-to-date performance is up 5.86%. Short-term trend indicators are bearishly aligned (SMA20 2.84%, SMA50 3.36%, SMA200 32.71%). The stock’s 14-day RSI is 55.73 (neutral), while the ATR of 3.39 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -5.08% below its high and over 116.84% above its low. Average 10-day trading volume of 122.88 thousand shares is slightly above the 3-month average of 86.03 thousand, indicating heightened recent market interest.

IRadimed Corporation generated EPS of $1.75 over the past year. Five-year average earnings growth is 73.91%. The latest quarter delivered EPS of $0.49. The next quarter is forecast at $0.45. Next year's EPS is expected at $15.28. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $116.00 to $116.00. The high target offers 33.73% upside. The low target suggests 33.73% downside. The mean target is $116.00. This offers 33.73% upside. IRadimed Corporation earnings surprise history is a mixed track record. The quarter that ended May 01, 2026, missed forecasts by 6.52%. The prior quarter beat by 10.2%. Over the last six quarters, Apple has recorded several small beats. These include -2.22% in February 13, 2025.

IRadimed Corporation has 12.72 million shares outstanding. The public float is 7.17 million shares, elevated short interest at 2.64% of float. This equals 212.13 thousand shares. The short ratio is 4.48 days. Institutional investors hold 94.38% of the float. Insiders own 36.61%. Susi Roger E. holds 2.19 million shares, HAWKINS JAMES B has 28.74 thousand shares and ALLEN MONTY K has 21.00 thousand shares. Over the past six months, insider transactions show net selling. They sold 52.12 thousand shares across 35 transactions.

IRadimed Corporation last paid a dividend of 1.21 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $60.79. This means the shares are trading above this model’s fair value.

IRadimed Corporation (NASDAQ:IRMD) closed at $86.74 USD, gaining $0.50 (0.58%) from the previous close of $86.24. The stock is currently mid-range between its 52-week high and low $50.88 and $107.90. With a market capitalization of about $1.11 billion, IRadimed Corporation is classified as a small-cap and shows market-like volatility (beta ~0.91). Key stats such as the average daily volume over the past year has been around 91.43 thousand shares, in line with its 52-week average. Headquartered in Winter Springs, FL, IRadimed Corporation operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Roger E. Susi, the company employs approximately 160 people and listed since July 16, 2014. IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally.

IRadimed Corporation trades at a P/E ratio of 46.87, slightly above the S&P 500 average, with a price-to-sales ratio of 12.83 and a price-to-book ratio of 11.23 reflecting a rich premium to book value. The P/FCF stands at 45.92, also above market averages. Compared to sector medians, IRadimed Corporation P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

IRadimed Corporation (NASDAQ:IRMD) shares are flat 5.86% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows IRadimed Corporation trading at a premium to the broader market with a P/E of 46.87. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $45.44, suggesting -47.61% downside. Our AI forecast model points to short-term weakness (-9.79% over two weeks), a medium-term rise (20.12% over three months), and a longer-term gain (19.88% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that IRadimed Corporation stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -9.79%, with price expected at $78.25 by May 20, 2026, within a range of $76.47 to $80.13 3-Month Outlook: Projected rise of 20.12%, reaching $104.19 by August 04, 2026, with a range of $102.91 to $105.75. 1-Year Outlook: Projected gain of 19.88%, with price at $103.98 by May 06, 2027, within a range of $99.97 to $107.42.